Table 4.
Alanine Aminotransferase (ALT) Concentrations in Study Participants Who Experienced ALT Flare
| ALT, IU/L | ||||||||
|---|---|---|---|---|---|---|---|---|
| Treatment Group | Participant number | Baseline | wk 4 | wk 8 | wk 12 | wk 16 | wk 20 | wk 24 |
| TDF (300 mg) | 9 | 245 | 679 | 69 | 23 | 18 | 22 | 18 |
| 102 | 119 | 243 | 555 | 99 | 41 | 33 | 23 | |
| Pradefovir | ||||||||
| 30 mg | 10 | 276 | 842 | 50 | 30 | 31 | 27 | 26 |
| 166 | 120 | 920 | 170 | 79 | 33 | ND | 24 | |
| 45 mg | 83 | 131 | 494 | 25 | 22 | 28 | 23 | 19 |
| 60 mg | 153 | 236 | 609 | 50 | 37 | 52 | 37 | 40 |
| 223 | 221 | 621 | 27 | 26 | 19 | 40 | 46 | |
| 75 mg | 105 | 255 | 565 | 42 | 68 | 83 | 75 | 29 |
Abbreviations: ALT, alanine aminotransferase; ND, not done; TDF, tenofovir disoproxil fumarate.